Advertisement

The Indian Journal of Pediatrics

, Volume 85, Issue 9, pp 748–756 | Cite as

Asthma and Medicines – Long-Term Side-Effects, Monitoring and Dose Titration

  • Satnam Kaur
  • Varinder Singh
Review Article

Abstract

Asthma is a major pediatric respiratory morbidity requiring long-term management. A thorough knowledge of long-term medication side-effects in children is, thus, essential for every physician dealing with childhood asthma. Establishing diagnosis and initiating treatment is just a beginning of the journey. Ongoing monitoring is an essential component of comprehensive asthma management programme. Monitoring includes not only assessment of asthma control but also checking for adherence to treatment, technique of inhaler device use, associated co-morbities, if any, and potential environmental exposure. Various tools – both subjective and objective - are available for assessment of asthma control. However, evidence for their optimum use in different settings and patient groups is lacking and monitoring has to be customized depending on available resources and individual patient characteristics. Patient education is an important component of long-term asthma therapy. The ultimate aim is to achieve optimum asthma control i.e., achieve and maintain control of clinical symptoms, decrease future risk to patients (risk of exacerbations, progressive loss of lung function and development of fixed airflow obstruction, adverse effects of medications) and enabling the child to lead a life without restrictions, at lowest possible dose of drugs. This article reviews the side-effects of medications used for long-term management of asthma and discusses current literature on asthma monitoring and dose titration in pediatric population to help the asthma therapist not only prescribe the drugs rationally but also help the family make right choices for treatment.

Keywords

Childhood asthma Management Side-effects Monitoring Dose titration Step-down 

Notes

Contributions

Both authors reviewed the topic and contributed to manuscript preparation. VS will act as guarantor for the paper.

Compliance with Ethical Standards

Conflict of Interest

None.

Source of Funding

None.

References

  1. 1.
    Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62:758–66.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–83.CrossRefPubMedGoogle Scholar
  3. 3.
    Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Dubus JC, Marguet C, Deschildre, et al. Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age and device. Allergy. 2001;56:944–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Shaw NJ, Edmunds AT. Inhaled beclomethasone and oral candidiasis. Arch Dis Child. 1986;61:788–90.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J. 1998;12:130–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61:518–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Evid Based Child Health. 2014;9:829–930.CrossRefPubMedGoogle Scholar
  9. 9.
    Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367:904–12.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Pruteanu AI, Chauhan BF, Zhang L, Prietsch SOM, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev. 2014;7:CD009878.Google Scholar
  12. 12.
    Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 μg/day. Eur Respir J. 1996;9:2263–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Axelsson I, Prietsch SOM, Zhang L. Inhaled corticosteroids in children with persistent asthma: effects of different drugs and delivery devices on growth. Cochrane Database Syst Rev. 2012;10  https://doi.org/10.1002/14651858.CD010126.
  15. 15.
    Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Schwartz RH, Neacsu O, Ascher DP, Alpan O. Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clin Pediatr (Phila). 2012;51:1184–90.CrossRefGoogle Scholar
  17. 17.
    Smith RW, Downey K, Gordon M, et al. Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid. Paediatr Child Health. 2012;17:e34–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Zöllner EW, Lombard CJ, Galal U, Hough FS, Irusen EM, Weinberg E. Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children. Pediatrics. 2012;130:e1512–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Issa-El-Khoury K, Kim H, Chan ES, Leek TV, Noya F. CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma. Allergy Asthma Clin Immunol. 2015;11:9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18:913–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Griffiths AL, Sim D, Strauss B, Rodda C, Armstrong D, Freezer N. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr Pulmonol. 2004;37:116–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Roux C, Kolta S, Desfougères J-L, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics. 2003;111:e706–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC, and the CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008;122:e53–61.Google Scholar
  24. 24.
    Tse SM, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG,  and the Childhood Asthma Management Program Research Group. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J Allergy Clin Immunol. 2012;130:53–60.e4.Google Scholar
  25. 25.
    Gafni RI, Baron J. Childhood bone mass acquisition and peak bone mass may not be important determinants of bone mass in late adulthood. Pediatrics. 2007;119:S131–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Raissy HH, Sternberg AL, Williams P, Jacobs A, Kelly HW; CAMP Research Group. Risk of cataracts in the Childhood Asthma Management Program Cohort, J Allergy Clin Immunol. 2010;126:389–92. 92.e1–4Google Scholar
  27. 27.
    Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63.CrossRefGoogle Scholar
  28. 28.
    Lee C, Klaustermeyer WB. Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma. Allergol Immunopathol (Madr). 2012;40:100–3.CrossRefGoogle Scholar
  29. 29.
    England RW, Nugent JS, Grathwohl KW, Hagan L, Quinn JM. High dose inhaled fluticasone and delayed hypersensitivity skin testing. Chest. 2003;123:1014–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Levy J, Zalkinder I, Kuperman O, et al. Effect of prolonged use of inhaled steroids on the cellular immunity of children with asthma. J Allergy Clin Immunol. 1995;95:806–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Yucel O, Eker Y, Nuhoglu C, Ceran O. Hemoglobin A1c levels in children with asthma using low dose inhaled corticosteroids. Indian Pediatr. 2009;46:300–3.PubMedGoogle Scholar
  32. 32.
    Wright NP, Wales JK. The incidence of hypoglycaemia in children with type 1 diabetes and treated asthma. Arch Dis Child. 2003;88:155–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    de Vries TW, De Langden-Wouterse JJ, Van Puijenbroek E, Duiverman EJ, De Jong-Van den Berg LT. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high-dose inhaled corticosteroids. BMJ. 1990;300:1548–51.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    de Vries TW, de Langen-Wouterse JJ, de Jong-Van den Berg LT, Duiverman EJ. Hypertrichosis as a side effect of inhaled steroids in children. Pediatr Pulmonol. 2007;42:370–3.CrossRefPubMedGoogle Scholar
  37. 37.
    McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting 2-adrenergic receptor agonists. Pediatrics. 2011;128:e1147–54.CrossRefPubMedGoogle Scholar
  38. 38.
    Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;11:CD007949.Google Scholar
  39. 39.
    Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94:60–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44:568–79.CrossRefPubMedGoogle Scholar
  41. 41.
    Kelly KD, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate in treatment of exercise-induced bronchoconstriction: a systematic review. Eur Respir J. 2001;17:39–45.CrossRefPubMedGoogle Scholar
  42. 42.
    Sridhar AV, Mckean MC. Nedochromil sodium for chronic asthma in children. Cochrane Database Syst Rev. 2006;3:CD004108.Google Scholar
  43. 43.
    Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.CrossRefPubMedGoogle Scholar
  44. 44.
    Pijnenburg MW, Baraldi E, Brand PLP, Carlsen K, Eber E, Frischer T. Monitoring asthma in children. Eur Respir J. 2015;45:906–25.CrossRefPubMedGoogle Scholar
  45. 45.
    Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax. 2015;70:543–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Brand PLP. The clinician’s guide on monitoring children with asthma. Paediatr Respir Rev. 2013;14:119–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Lu M, Wu B, Che D, Qiao R, Gu H. FeNO and asthma treatment in children: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e347.CrossRefGoogle Scholar
  48. 48.
    Bush A, Eber E. The value of FeNO measurement in asthma management: the motion for yes, it's NO–or, the wrong end of the stick. Paediatr Respir Rev. 2008;9:127–31.CrossRefPubMedGoogle Scholar
  49. 49.
    Boulet L-P, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clin Chest Med. 2012;33:405–17.CrossRefPubMedGoogle Scholar
  50. 50.
    Trent CA, Zimbro KS, Rutledge CM. Barriers in asthma care for pediatric patients in primary care. J Pediatr Health Care. 2015;29:70–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Rottier BL, Eber E, Hedlin G, Turner S, Wooler E. Monitoring asthma in childhood: management-related issues. Eur Respir Rev. 2015;24:194–203.CrossRefPubMedGoogle Scholar
  52. 52.
    Caponoglu M, Dibek Misirlioglu E, Toyran M, Civelak E, Kocabas CN. Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhaler. J Asthma. 2015;52:838–45.CrossRefGoogle Scholar
  53. 53.
    Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897.CrossRefPubMedGoogle Scholar
  54. 54.
    Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007;62:1–41.CrossRefPubMedGoogle Scholar
  55. 55.
    Blondeau K, Mertens V, Dupont L, et al. The relationship between gastroesophageal reflux and cough in children with chronic unexplained cough using combined impedance-pH-manometry recordings. Pediatr Pulmonol. 2011;46:286–94.CrossRefPubMedGoogle Scholar
  56. 56.
    Holbrook JT, Wise RA, Gold BD, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012;307:373–81.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011;127:741–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  1. 1.Department of PediatricsVardhman Mahavir Medical College and Associated Safdarjung HospitalNew DelhiIndia
  2. 2.Department of PediatricsLady Hardinge Medical College and Associated Kalawati Saran Children’s HospitalNew DelhiIndia

Personalised recommendations